ARK Genomic Revolution ETF (ARKG) Delivers +25% Gains Over 30 Days Amid Genomics Rally
Key Takeaways
- ARKG surged approximately 25% over the last 30 days, driven by a powerful rally across genomics, precision medicine, and AI-enabled drug discovery holdings.
- The fund has gained roughly 54% over the last quarter, reflecting a sustained rotation into innovative healthcare and biotechnology equities.
- Top holdings including TWST, TEM, CRSP, and TXG contributed disproportionately to recent gains amid sector-wide momentum.
- Renewed investor appetite for growth-oriented, small- and mid-cap biotechnology names has amplified the fund's upward trajectory.
- Macroeconomic tailwinds, including moderating interest rate expectations, have provided additional support for long-duration innovation assets.
ARK Genomic Revolution ETF (ARKG) Overview and Portfolio Exposure
The ARK Genomic Revolution ETF is an actively managed exchange-traded fund that seeks long-term growth of capital by investing at least 80% of its assets in domestic and foreign equity securities tied to the genomics revolution. The fund concentrates its exposure in the healthcare sector, with a particular emphasis on biotechnology, life sciences tools and services, and health care technology companies. ARKG typically holds between 40 and 60 positions, though the portfolio has recently carried approximately 33 names, reflecting the fund manager's high-conviction approach.
As of early July 2026, the fund's largest holdings included Twist Bioscience Corp (TWST), Tempus AI Inc (TEM), CRISPR Therapeutics AG (CRSP), 10X Genomics Inc (TXG), and Absci Corp (ABSI). The portfolio is heavily tilted toward small- and mid-cap companies, with approximately 40% of assets in small-cap names and another 41% in mid-cap stocks. The fund carries an expense ratio of 0.75% and had net assets of approximately $1.3 billion. This concentrated, innovation-heavy structure makes ARKG highly sensitive to shifts in risk sentiment, sector rotation, and clinical or regulatory catalysts affecting its underlying holdings. I also checked this using Tickeron’s AI Screener to see how the holdings stack up against peers in the sector.
ARK Genomic Revolution ETF (ARKG) Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ARKG has advanced approximately 25%, climbing from around $32.85 in mid-June to $41.01 by mid-July 2026. The move was not linear; the fund experienced several sharp upward bursts interspersed with brief consolidation periods, characteristic of momentum-driven rallies in high-beta thematic ETFs.
The quarterly performance has been even more pronounced. From approximately $26.68 in early April, ARKG has surged roughly 54%, marking one of the strongest three-month stretches for the fund in recent years. The rally accelerated in late May and continued through June, with the fund breaking through multiple resistance levels as buying pressure intensified. This sustained upward trend suggests broad-based participation rather than a short-lived spike driven by a single event.
What Drove ARKG Price in the Last 30 Days
Several converging factors fueled ARKG's 25% advance over the past month. The most significant driver was the powerful rally in the fund's top holdings. Twist Bioscience (TWST), a DNA synthesis company, and Tempus AI (TEM), an AI-powered precision medicine platform, both experienced substantial price appreciation as investor enthusiasm for the intersection of artificial intelligence and healthcare intensified. CRISPR Therapeutics (CRSP) and 10X Genomics (TXG) also contributed meaningfully, benefiting from positive clinical developments and growing adoption of genomic analysis tools.
Broader macroeconomic conditions provided a supportive backdrop. Moderating inflation data and shifting expectations around Federal Reserve policy reduced the discount rate applied to future cash flows, disproportionately benefiting long-duration growth assets like those held in ARKG. The biotechnology sector broadly outperformed the wider market during this period, with the small- and mid-cap segment showing particular strength. Additionally, renewed M&A (mergers and acquisitions) speculation across the genomics and precision medicine landscape added a layer of takeover premium to several portfolio companies. Fund inflows into thematic healthcare ETFs also accelerated, creating additional demand pressure on underlying holdings.
What Drove ARKG Performance Over the Last Quarter
The fund's 54% quarterly surge reflects a broader regime change in market leadership that began taking shape in April 2026. After an extended period of underperformance for innovation-focused strategies, capital began rotating back into high-growth biotechnology and genomics names. This rotation was underpinned by improving fundamentals across the precision medicine industry, including accelerating revenue growth at several top holdings, successful clinical trial readouts, and expanding commercial adoption of gene editing and molecular diagnostics technologies.
Institutional positioning played a meaningful role. After several quarters of outflows from thematic healthcare ETFs, the second quarter of 2026 saw a reversal, with net inflows returning to the category. The fund's concentrated exposure to AI-enabled drug discovery platforms proved especially timely, as the convergence of machine learning and biology emerged as a dominant investment narrative. Large-cap anchor holdings such as Illumina (ILMN) and Natera (NTRA) provided additional stability, while smaller positions amplified returns during risk-on periods. The combination of sector rotation, improving fundamentals, and renewed capital inflows created a powerful tailwind that sustained the rally across the entire quarter.
Using Tickeron’s AI Screener in My Research Process
Identifying ETFs and stocks with strong momentum before they make outsized moves can be challenging without the right tools. As part of my ongoing analysis, I frequently rely on Tickeron’s AI Screener, an AI-powered discovery platform designed to help investors scan thousands of securities using technical indicators, fundamental metrics, volatility measures, price patterns, industry filters, and AI-generated trading signals. The screener enables users to surface trending securities, breakout candidates, and emerging opportunities across sectors far more efficiently than manual research. For investors seeking to monitor genomics, biotechnology, or other thematic segments, the AI Screener offers a structured, data-driven approach to idea generation and portfolio surveillance. In my view, this kind of tool has become increasingly valuable for staying on top of fast-moving themes like the one driving ARKG right now.
ARKG ETF Outlook: What Investors Should Watch Next
Looking ahead, several factors will likely shape ARKG's trajectory. The macroeconomic environment remains central; any shift in interest rate expectations or inflation data could rapidly alter the discount rate applied to the fund's long-duration holdings. The genomics and precision medicine sector is also entering a season of major medical conferences and potential clinical data presentations, which could serve as catalysts for individual holdings and the broader theme.
Investors should monitor the earnings reports and guidance from the fund's largest positions, particularly Twist Bioscience, Tempus AI, CRISPR Therapeutics, and 10X Genomics, as these will provide insight into commercial execution and revenue growth trajectories. Regulatory developments affecting gene editing technologies, diagnostic approvals, and AI-enabled drug discovery platforms also warrant close attention. Capital flows into thematic ETFs will indicate whether the recent rotation into innovation strategies has staying power. While the fund's concentrated, high-beta structure amplifies gains during favorable conditions, it equally magnifies downside risk during periods of sector rotation or risk-off sentiment, making position sizing and portfolio context important considerations for any investor evaluating exposure to the genomics revolution. I’m watching this closely as the next round of data and policy signals comes in.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
Momentum Indicator for ARKG turns positive, indicating new upward trend
ARKG saw its Momentum Indicator move above the 0 level on September 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned positive. In 80 of the 83 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARKG just turned positive on September 17, 2026. Looking at past instances where ARKG's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +6.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 242 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 194 of 215 cases where ARKG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement